Literature DB >> 28215539

Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis.

Elie El Rassy1, Tarek Assi2, Fadi El Karak2, Marwan Ghosn2, Joseph Kattan2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28215539     DOI: 10.1016/j.clinre.2016.11.012

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


× No keyword cloud information.
  6 in total

Review 1.  Current Standards of Chemotherapy for Pancreatic Cancer.

Authors:  May Tun Saung; Lei Zheng
Journal:  Clin Ther       Date:  2017-09-19       Impact factor: 3.393

Review 2.  Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives.

Authors:  Wonhee Woo; Edward T Carey; Minsig Choi
Journal:  Onco Targets Ther       Date:  2019-02-21       Impact factor: 4.147

3.  Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer.

Authors:  Victor H F de Jesus; Marcos P G Camandaroba; Vinicius F Calsavara; Rachel P Riechelmann
Journal:  Ther Adv Med Oncol       Date:  2020-02-28       Impact factor: 8.168

4.  Retrospective analysis of efficacy and safety of Gemcitabine-based chemotherapy in patients with metastatic pancreatic adenocarcinoma experiencing disease progression on FOLFIRINOX.

Authors:  Victor Hugo Fonseca de Jesus; Marcos Pedro Guedes Camandaroba; Mauro Daniel Spina Donadio; Audrey Cabral; Thiago Pimentel Muniz; Luciana de Moura Leite; Lucas Ferreira Sant'Ana
Journal:  J Gastrointest Oncol       Date:  2018-10

5.  Clinical Trials in Pancreatic Cancer: A Long Slog.

Authors:  Thomas Enzler; Susan Bates
Journal:  Oncologist       Date:  2017-10-05

6.  Intra-arterial infusion chemotherapy versus isolated upper abdominal perfusion for advanced pancreatic cancer: a retrospective cohort study on 454 patients.

Authors:  Karl R Aigner; Sabine Gailhofer; Emir Selak; Kornelia Aigner
Journal:  J Cancer Res Clin Oncol       Date:  2019-09-10       Impact factor: 4.553

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.